D-0513-2019 Class III Terminated

Recalled by Lupin Pharmaceuticals Inc. — Baltimore, MD

FDA drug recall D-0513-2019 was initiated by Lupin Pharmaceuticals Inc. on Feb 13, 2019 and is designated Class III. Reason for recall: CGMP Deviations: Finished product made with lovastatin drug substance that was out of specification for individual impurity results. The recall status is terminated (terminated Oct 6, 2020). Affected quantity: 44,640 bottles.

Recall details

Product Type
Drugs
Report Date
Feb 27, 2019
Initiation Date
Feb 13, 2019
Termination Date
Oct 6, 2020
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
44,640 bottles

Product description

Lovastatin Tablets USP, 40 mg, packaged in a) 60-count (NDC 68180-469-07 and b) 100-count (NDC 68180-469-01) bottles, Rx only, Manufactured for: Lupin Pharmaceuticals, Inc., Baltimore, Maryland 21202; Manufactured by: Lupin Limited, Goa 403 722 INDIA.

Reason for recall

CGMP Deviations: Finished product made with lovastatin drug substance that was out of specification for individual impurity results.

Distribution pattern

Nationwide in the USA and Puerto Rico.

Code information

Lot #: a) G702755, Exp March 2020; b) G702756, Exp March 2020

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0513-2019
openFDA file date
Nov 16, 2026
Loaded by RegDataLab
Nov 17, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-0513-2019. Report a data issue: hello@regdatalab.com.